October 28, 2024
TOPLINE: Adding pembrolizumab to adjuvant chemotherapy in the first-line setting improved disease-free survival (DFS) in patients with high-risk endometrial cancer who have mismatch repair–deficient (dMMR) tumors, […]
October 28, 2024
TOPLINE: Atezolizumab combined with targeted therapy improved median overall survival to 19 months in patients with anaplastic thyroid carcinoma (ATC). The longest survival was observed in […]
October 28, 2024
TOPLINE: Stroke rates in Californians with sickle cell disease (SCD) have increased in both children and adults in the post-STOP era. The cumulative incidence of first […]
October 25, 2024
TOPLINE: Older non-Hispanic Black adults with breast cancer are less likely to receive guideline-concordant care and timely treatment than non-Hispanic White adults, according to findings from […]
October 25, 2024
NEW YORK — When patients with multiple myeloma (MM) relapse following chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies (BsABs), or both, likely salvage options remain […]
October 24, 2024
The incidence of lung cancer in never-smokers (LCINS) is increasing, and experts think climate change may be driving this. LCINS differs histologically and epidemiologically from smoking-related […]
October 24, 2024
NEW YORK — In a three-way debate on whether to prioritize chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies (BsAbs), or one of the novel oral […]
October 24, 2024
NEW YORK — In the wake of details about the molecular pathophysiology of Waldenström macroglobulinemia (WM), an expert gave an update on current and expanding options […]
October 24, 2024
TOPLINE: A recent study found that long-term exposure to fine particulate matter ≤ 2.5 μm (PM2.5) is associated with an increased risk for breast cancer, with […]